MEDIAN Technologies: Transforming Image Interpretation to Quantitative Science
pharmatechoutlook

MEDIAN Technologies: Transforming Image Interpretation to Quantitative Science

CIO VendorFredrik Brag CEO
Technological evolution instituted by the confluence of trends such as social media, mobile, Big Data analytics, and cloud have transformed businesses across industries to revamp their practices through effective utilization of relevant data. In the pharmaceutical and life sciences sphere, organizations have left no stone unturned while leveraging technology to unlock insights from existing data sources—Electronic Health Records (EHRs), demographic information of patients, treatment history, claims data, and clinical trial reports. Today, a dizzying number of digital and smart devices and imaging solutions that are supported with real-time information are contributing toward the development of drugs and clinical research. However, pharma companies are not resilient enough to embrace new technologies due to high cost involved in their implementation and ownership. “The cost of developing new drugs is constantly increasing and the whole process needs to be streamlined. New imaging biomarkers and integrated imaging platform play a pivotal role in oncology drug development. That's where eClinical solutions can help,” says Fredrik Brag, CEO, MEDIAN Technologies. Greater Boston based MEDIAN Technologies transforms image interpretation from an objective art to quantitative science to facilitate better and more reliable treatment outcomes for cancer patients.

The organization provides advanced medical imaging software products and integrated services for oncology drug development. MEDIAN’s Clinical Trial Imaging Service standardizes investigator and independent reviews to streamline data management workflow, reduce variability and censoring bias, and extract advanced imaging biomarkers. MEDIAN LMS – Lesion Management Solution is a comprehensive portfolio of web based clinical applications of the firm that can be used for the management of data generated by the evaluation of cancerous lesions diagnosed in scans from all modalities. The automation of routine image management tasks creates speed and efficiency, reduces human error in reviews and increases the reproducibility in image read results.

The cost of developing new drugs is constantly increasing and the whole process needs to be streamlined. New imaging biomarkers and integrated imaging platform play a pivotal role in oncology drug development. That's where eClinical solutions can help


LMS serves as a decision making tool for monitoring the disease and evaluating treatment efficacy and can be deployed in picture archiving and communication system (PACS) or radiology information system (RIS) workstations.

With a strong scientific and technological expertise in determining disease biomarkers from medical images, MEDIAN uses advanced algorithms that help detect, quantify, and track lesions or abnormalities identified in medical images. The image analysis capabilities of the company’s imaging technology platform enable the design, implementation, and validation of advanced imaging of biomarkers.

Since its inception, the firm has carved a niche as a prominent solution provider that works toward augmenting the quality of life of cancer patients and helping them overcome disease impacts. The firm has formed strategic partnerships with several leading CRO’s, and collaborates its offerings to provide integrated imaging services for clinical trials. Additionally, MEDIAN associates with Canon to develop new imaging technologies, and address the need of the organizations operating in the patient care market. To promote innovation, the firm also works with South Texas Accelerated Research Therapeutics (START), which is dedicated toward conducting Phase I trials in oncology.

For the road ahead, MEDIAN plans to expand its operations across the U.S. and Asian markets. “We are also planning to develop our product offerings into new therapeutic areas,” concludes Brag.